The Strategic Durability of Digital Product Passports:A New Perspective to Raise the Ambition

Digital product passports (DPP) are identified as a key element to contribute to the circular economy. DPP focuses primarily on the collection of product and material information from a manufacturing perspective all the way throughout the supply chain and is planned to be implemented through policy development toward 2030. However, we argue that if we unfold the strategic potential of DPP to make it more attractive to companies, we can speed up this implementation. Accordingly, this paper goes beyond the environmental benefits of DPP by proposing a conceptual framework for DPP services that can increase the product’s value both from a user, market and company perspective. Through the concept of strategic durability, the paper contributes with a new perspective on DPPs, namely how companies through digital passport services can: 1) strengthen relationships to customers, 2) sustain and accentuate the company’s values and competencies, and 3) generate long-lasting competitive advantage in the market. Finally, the paper qualifies the new concept for digital passport services based on a company case (Fritz Hansen A/S) to exemplify what this conceptualization will mean in the furniture industry.Digital product passports (DPP) are identified as a key element to contribute to the circulareconomy. DPP focuses primarily on the collection of product and material information from amanufacturing perspective all the way throughout the supply chain and is planned to be implemented through policy development toward 2030. However, we argue that if we unfold the strategic potential of DPP to make it more attractive to companies, we can speed up this implementation. Accordingly, this paper goes beyond the environmental benefits of DPP by proposing a conceptual framework for DPP services that can increase the product’s value both from a user, market and company perspective. Through the concept of strategic durability, the paper contributes with a new perspective on DPPs, namely how companies through digital passport services can: 1) strengthen relationships to customers, 2) sustain and accentuate the company’s values and competencies, and 3) generate long-lasting competitive advantage in the market. Finally, the paper qualifies the new concept for digital passport services based on a company case (Fritz Hansen A/S) to exemplify what this conceptualization will mean in the furniture industry

Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed aml and overall survival in patients with npm1 and flt3 mutations

Purpose To determine the optimal induction chemotherapy regimen for younger adults with newly diagnosed AML without known adverse risk cytogenetics. Patients and Methods One thousand thirty-three patients were randomly assigned to intensified (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin [FLAG-Ida]) or standard (daunorubicin and Ara-C [DA]) induction chemotherapy, with one or two doses of gemtuzumab ozogamicin (GO). The primary end point was overall survival (OS). Results There was no difference in remission rate after two courses between FLAG-Ida + GO and DA + GO (complete remission [CR] + CR with incomplete hematologic recovery 93% v 91%) or in day 60 mortality (4.3% v 4.6%). There was no difference in OS (66% v 63%; P = .41); however, the risk of relapse was lower with FLAG-Ida + GO (24% v 41%; P < .001) and 3-year event-free survival was higher (57% v 45%; P < .001). In patients with an NPM1 mutation (30%), 3-year OS was significantly higher with FLAG-Ida + GO (82% v 64%; P = .005). NPM1 measurable residual disease (MRD) clearance was also greater, with 88% versus 77% becoming MRD-negative in peripheral blood after cycle 2 (P = .02). Three-year OS was also higher in patients with a FLT3 mutation (64% v 54%; P = .047). Fewer transplants were performed in patients receiving FLAG-Ida + GO (238 v 278; P = .02). There was no difference in outcome according to the number of GO doses, although NPM1 MRD clearance was higher with two doses in the DA arm. Patients with core binding factor AML treated with DA and one dose of GO had a 3-year OS of 96% with no survival benefit from FLAG-Ida + GO. Conclusion Overall, FLAG-Ida + GO significantly reduced relapse without improving OS. However, exploratory analyses show that patients with NPM1 and FLT3 mutations had substantial improvements in OS. By contrast, in patients with core binding factor AML, outcomes were excellent with DA + GO with no FLAG-Ida benefit